Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620000881932
Ethics application status
Approved
Date submitted
21/06/2020
Date registered
4/09/2020
Date last updated
4/09/2020
Date data sharing statement initially provided
4/09/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
NODE Study - Randomised Trial of Extended Pelvic Lymph Node Dissection In Patients Undergoing Robotic-Assisted Radical Prostatectomy For High-Risk Prostate Cancer
Query!
Scientific title
NODE Study - Randomised Trial of Extended Pelvic Lymph Node Dissection In Patients Undergoing Robotic-Assisted Radical Prostatectomy For High-Risk Prostate Cancer
Query!
Secondary ID [1]
301554
0
None
Query!
Universal Trial Number (UTN)
U1111-1253-7691
Query!
Trial acronym
NODE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate cancer
317958
0
Query!
Condition category
Condition code
Cancer
315993
315993
0
0
Query!
Prostate
Query!
Surgery
316233
316233
0
0
Query!
Other surgery
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The intervention will be the performance of an extended pelvic lymph node dissection (ePLND).
This procedure is performed during surgery for prostate cancer - specifically during a robotic radical prostatectomy, the current standard of care.
Currently the procedure is performed variably by different urologists. Current guidelines recommend it being performed only in high risk patients. The procedure involves removal of many of the lymph nodes in the pelvis, and if cancer has spread to the lymph nodes, may help to remove all the cancer.
To ensure consistency of surgery, surgeons will be required to take photos of the areas from which they have removed the lymph nodes to ensure enough has been taken out.
The intervention will be performed by 3 experienced consultant urologists at the Chris O'Brien Lifehouse Hospital and Royal Prince Alfred Hospital.
As a pilot, 20 patients will be recruited, this is to ensure that recruitment for a larger trial is possible and to ensure that adherence to the protocol by the surgeons is possible.
The ePLND is expected to approximately 1 hour to the procedure, which currently takes 2-4 hours.
Specific training is not required to perform the ePLND, though these surgeons have significant experience performing it.
One of the researcher team will be present at all of the cases to monitor for protocol violations, after the pilot study recruitment is completed all patients will have a chart review, review of intraoperative images and initial data to assess for protocol violations.
Query!
Intervention code [1]
317881
0
Treatment: Surgery
Query!
Comparator / control treatment
The control group will undergo a robotic radical prostatectomy without the lymph node dissection.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
324196
0
Proportion of eligible patients able to be recruited into the study.
Query!
Assessment method [1]
324196
0
Query!
Timepoint [1]
324196
0
From commencement of the study to final patient intervention.
Query!
Secondary outcome [1]
383987
0
Number of enrolled subjects with protocol violations
- protocol violations would be any deviation from the defined course
Examples would include:
- patients randomised to no node dissection having a node dissection
- an incomplete dissection being performed or photos not being taken adequately
- inadequate follow up
Query!
Assessment method [1]
383987
0
Query!
Timepoint [1]
383987
0
At any time throughout recruitment and follow up. Follow up ceases 12 months following intervention.
Query!
Secondary outcome [2]
383988
0
Adverse events
Adverse events related to:
- the lymph node dissection intraoperatively- eg vessel injury, nerve injury
- the longer length of surgery - eg pressure sore, neuropraxia
- the lymph node dissection postoperatively - eg lymphocele
Other adverse events related to surgery - eg post operative infection, thromboembolic events
These will be collected from hospital records
Query!
Assessment method [2]
383988
0
Query!
Timepoint [2]
383988
0
At any point from intervention to completion of follow up 12 months later.
Query!
Secondary outcome [3]
383990
0
Biochemical recurrence on PSA (prostate specific antigen) blood test
Query!
Assessment method [3]
383990
0
Query!
Timepoint [3]
383990
0
6 week, 3 month, 6 month and 12 months post-operatively.
Query!
Secondary outcome [4]
384010
0
Clinical recurrence - composite secondary outcome
Symptomatic recurrence
Radiological evidence of localised recurrence or distant metastases.
- determined by the presence of cancer in the prostate bed or elsewhere on abdominal/pelvic computed tomography (CT) scan, bone scintigraphy, MRI or prostate-specific membrane antigen (PSMA)-PET
Query!
Assessment method [4]
384010
0
Query!
Timepoint [4]
384010
0
Any point in the 12 months following the procedure
Query!
Secondary outcome [5]
384011
0
Survival
Query!
Assessment method [5]
384011
0
Query!
Timepoint [5]
384011
0
Date of death or alive at 12 months following procedure
Query!
Eligibility
Key inclusion criteria
Histologically proven prostate cancer scheduled for robotic assisted radical prostatectomy
Non-metastatic, high risk or very high risk disease, defined as one or more of:
- Stage >T3a
- A histological grading on biopsy of ISUP Grade Group 4 (Gleason 4+4=8) or higher,
- Prostate specific antigen (PSA) >20ng/ml
Prostate-specific membrane antigen (PSMA)-PET negative for metastatic disease
The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of deep venous thrombosis
- History of lower limb lymphoedema
- History of previous pelvic radiotherapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation by contacting central randomisation off site at ANZUP Cancer trials group
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Unstratified blocked randomisation using computer generated random number table
Blocks of 4
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
14/09/2020
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
14/09/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
14/09/2022
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
16958
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
16959
0
The Chris O’Brien Lifehouse - Camperdown
Query!
Recruitment postcode(s) [1]
30617
0
2050 - Camperdown
Query!
Funding & Sponsors
Funding source category [1]
305988
0
Hospital
Query!
Name [1]
305988
0
Chris O'Brien Lifehouse Hospital
Query!
Address [1]
305988
0
119-143 Missenden Rd, Camperdown NSW 2050
Query!
Country [1]
305988
0
Australia
Query!
Funding source category [2]
306017
0
Hospital
Query!
Name [2]
306017
0
Royal Prince Alfred Hospital
Query!
Address [2]
306017
0
50 Missenden Rd, Camperdown NSW 2050
Query!
Country [2]
306017
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Chris O'Brien Lifehouse Hospital
Query!
Address
119-143 Missenden Rd, Camperdown NSW 2050
Query!
Country
Australia
Query!
Secondary sponsor category [1]
306449
0
Hospital
Query!
Name [1]
306449
0
Royal Prince Alfred Hospital
Query!
Address [1]
306449
0
50 Missenden Rd, Camperdown NSW 2050
Query!
Country [1]
306449
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
306227
0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Query!
Ethics committee address [1]
306227
0
Research Ethics and Governance Office (REGO)
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050
Query!
Ethics committee country [1]
306227
0
Australia
Query!
Date submitted for ethics approval [1]
306227
0
07/04/2019
Query!
Approval date [1]
306227
0
25/02/2020
Query!
Ethics approval number [1]
306227
0
2019/ETH09765
Query!
Summary
Brief summary
The purpose of this pilot study is to determine whether it is possible to recruit sufficient participants in a trial investigating the role of extended pelvic lymph node dissection in addition to the removal of the prostate gland for the treatment of prostate cancer.
Who is it for?
You may be eligible for this study if you are an adult with prostate cancer who has already been scheduled for robotic assisted radical prostatectomy.
Study details
Participants in this study will receive one of two treatments:
1. Removal of the prostate gland, or
2. Removal of the prostate gland plus removal of pelvic lymph nodes
Both surgeries will be completed using robotic assistance, as is the standard of care. The treatment the participant will receive will be decided randomly. All participants will be followed up for 12 months for recurrences of cancer, side effects and overall survival.
Following the procedure, you would be required to undergo regular blood tests, and possibly radiological scans to monitor for cancer recurrence.
It is hoped that this research will determine if a larger trial can be completed on extended lymph node dissection, and that the larger trial will help determine if extended lymph node dissection is beneficial over a radical prostatectomy.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
103166
0
Prof Henry Woo
Query!
Address
103166
0
Lifehouse Hospital
119-143 Missenden Rd, Camperdown NSW 2050
Query!
Country
103166
0
Australia
Query!
Phone
103166
0
+61 02 90527586
Query!
Fax
103166
0
Query!
Email
103166
0
[email protected]
Query!
Contact person for public queries
Name
103167
0
Dr George McClintock
Query!
Address
103167
0
Lifehouse Hospital
119-143 Missenden Rd, Camperdown NSW 2050
Query!
Country
103167
0
Australia
Query!
Phone
103167
0
+61 1300852500
Query!
Fax
103167
0
Query!
Email
103167
0
[email protected]
Query!
Contact person for scientific queries
Name
103168
0
Dr George McClintock
Query!
Address
103168
0
Lifehouse Hospital
119-143 Missenden Rd, Camperdown NSW 2050
Query!
Country
103168
0
Australia
Query!
Phone
103168
0
+61 1300852500
Query!
Fax
103168
0
Query!
Email
103168
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF